AYTU BIOPHARMA, INC Available-for-sale Securities, Gross Unrealized Loss
AYTU BIOPHARMA, INC (AYTU) reported Available-for-sale Securities, Gross Unrealized Loss of $292.45 thousand for the 3-month period ending 2017-03-31, per its 10-Q filed 2017-05-11.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AvailableForSaleSecuritiesGrossUnrealizedLoss · last filed 2017-05-11
- AYTU BIOPHARMA, INC available-for-sale securities, gross unrealized loss for the quarter ending 2017-03-31 was $292.45K.
- AYTU BIOPHARMA, INC available-for-sale securities, gross unrealized loss for the quarter ending 2016-03-31 was $0.00.
| Period end | Available-for-sale Securities, Gross Unrealized Loss 3 month | Available-for-sale Securities, Gross Unrealized Loss 9 month |
|---|---|---|
| 2017-03-31 | $292.45K 10-Q · filed 2017-05-11 | $292.45K 10-Q · filed 2017-05-11 |
| 2016-03-31 | $0.00 10-Q · filed 2017-05-11 | $0.00 10-Q · filed 2017-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |